In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Annals Meeting Reports (7)

Edited by Edited by Annals of the New York Academy of Sciences editorial staff
Annals Meeting Reports (7)

Published: October 2011

Volume 0

Three concise summaries of conferences on immunology, on mechanisms of allocating resources across disciplines, and on drug discovery for schizophrenia.
Learn More

This volume presents three meeting reports. (1) Toward an interdisciplinary science of consumption; (2) Wild immunology: converging on the real world; and (3) Advancing drug discovery for schizophrenia.

Scientific perspectives on the drive to consume were presented in Ann Arbor, Michigan, at the conference entitled “The Interdisciplinary Science of Consumption: Mechanisms of Allocating Resources Across Disciplines.” The meeting, which took place May 12–15, 2010 and was sponsored by Rackham Graduate School and the Department of Psychology at the University of Michigan, included presentations on human, primate, and rodent models and spanned multiple domains of consumption, including reward seeking, delay discounting, food-sharing reciprocity, and the consumption and display of material possessions across the life span.

Centre for Immunity, Infection, and Evolution (CIIE) sponsored a one-day symposium entitled “Wild Immunology”. The CIIE is a new Wellcome Trust-funded initiative with the remit to connect evolutionary biology and ecology with research in immunology and infectious diseases in order to gain an interdisciplinary perspective on challenges to global health. The central question of the symposium was, “Why should we try to understand infection and immunity in wild systems?” Specifically, how does the immune response operate in the wild and how do multiple coinfections and commensalism affect immune responses and host health in these wild systems? The symposium brought together a broad program of speakers, ranging from laboratory immunologists to infectious disease ecologists, working on wild birds, feral animals, wild and laboratory rodents and on questions ranging from the dynamics of coinfection to how commensal bacteria affect the development of the immune system. The meeting on wild immunology, organized by Amy Pedersen, Simon Babayan, and Rick Maizels, was held at the University of Edinburgh, UK on 30th June, 2011.

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, “Advancing Drug Discovery for Schizophrenia” was held March 9–11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.